Experience with abatacept used in the treatment of patients with rheumatoid arthritis
https://doi.org/10.14412/1995-4484-2011-513
Abstract
The efficiency and safety of therapy with abatacept in combination with methotrexate were studied in patients with rheumatoid arthritis. The performed therapy was shown to reduce the activity of an immune inflammatory process and the magnitude of articular syndrome and to improve the patients' functional status.
About the Authors
V I MazurovSergei Vladimirovich Dolgikh
E S Zhugrova
Yu B Shulman
R R Samigullina
References
1. <div><p>Ревматология: Клинические рекомендации.Под ред. акад. РАМН Е.Л. Насонова. 2-е изд.,испр. и доп. М.: ГЭОТАР-Медиа, 2010;752 с.</p><p>Мазуров В.И., Лила А.М. Ревматоидныйартрит. Клиническая ревматология. Под ред.В.И. Мазурова. СПб: Фолиант, 2005;87–140.</p><p>Насонов Е.Л., Чичасова Н.В. Рациональная терапия ревматоидного артрита. М.:Миклош, 2010;224 с.</p><p>Диффузные болезни соединительной ткани: Руководство для врачей. Под ред. проф.В.И. Мазурова. СПб.: СпецЛит, 2009;192 с.</p><p>Лукина Г.В., Сигидин Я.А., Позднякова Е.С. и др. Инфликсимаб в терапии ревматоидного артрита. Науч-практич ревматол 2007;4:60–5.</p><p>Kremer J.M., Genant H.K., Moreland L.W. et al. Effect of abatacept in patients with methotrexate-resistant active rheumatoid arthritis. N Engl J Med 2005;353:1114–23.</p><p>Schiff M., Keiserman M., Codding C. et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomized, double blind, placebo-controlled study in patients with rheumatoid arthritis andan inadequate response to methotrexate. Ann Rheum Dis 2008;67:1096–103.</p><p>Schiff M., Pritchard C. et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis 2009;68;1708–14.</p><p>Genovese M.C., Schiff M., Luggen M. et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy Ann Rheum Dis 2008;67:547–54.</p></div><br />
Review
For citations:
Mazurov V.I., Dolgikh S.V., Zhugrova E.S., Shulman Yu.B., Samigullina R.R. Experience with abatacept used in the treatment of patients with rheumatoid arthritis. Rheumatology Science and Practice. 2011;49(6):14-16. (In Russ.) https://doi.org/10.14412/1995-4484-2011-513
Views:
1093
Email this article 